NEW YORK – Chinese precision oncology company Genetron Health has formed a strategic partnership with Beijing InnoCare Pharma Tech (InnoCare) to provide clinical trial genomic testing and companion diagnostic development services for InnoCare's biomarker-driven oncology drug development.
Additional details of the agreement were not disclosed.
Genetron, based in Beijing, provides comprehensive genomic profiling services for drug research and development. Its services include biomarker evaluation, for molecularly targeted therapy and immunotherapy, clinical trial enrollment and testing, companion diagnostic development and commercialization, and joint-marketing post-drug approval.
The firm offers a National Medical Products Administration-approved technology platform covering next-generation sequencing, digital PCR, and qPCR for companion diagnostics development, and it can provide customized and integrated diagnostic assay development and commercialization services to biopharmaceutical companies.
Last week Genetron said that it received NMDA approval for an NGS system and kit for an eight-gene lung cancer panel.